Kuwait: Ali Abdulwahab Al Mutawa (AAW) for Pharma and Medical Equipment has signed a Memorandum of Understanding (MoU) with Nice University Hospital (CHU Nice) to explore areas of collaboration and investment in the medical sector and its related services. CHU Nice is a member of the Nice Côte d'Azur University (UCA) in France. 

The agreement was signed at AAW headquarters by AAW Chairman and CEO Mr. Faisal Al-Mutawa and CHU Nice General Manager Mr. Charles Guépratte. Attendees included AAW Pharma and ME Manager Mr. Moustafa Allam, CHU Nice Director of Medical Affairs and International Relations Ms. Pauline Robineau, AAW General Manager - Legal Department Mr. Adib Dib, and AAW Legal Consultant Mr. Philippe Gedeon.

The MoU works in-line with Kuwait’s Vision 2035 and national development plan which aims to improve the quality of health in the country and enhance the capabilities of the national workforce. The signed agreement stems from AAW’s continuing role to support the development of the medical and pharmaceutical sector in Kuwait to benefit from international expertise that facilitates knowledge transfer among professionals and health awareness among the community.

AAW Chairman and CEO Mr. Faisal Ali Al Mutawa, said: “We are pleased to partner with Nice University Hospital in France, to provide us with the technical and support services we need to advance the quality of health services in Kuwait. The French healthcare system is recognized globally for its great quality of service and credibility and is considered among the best in the world. Today we are partnering with one of the most reputable French healthcare institutes in the world to help us to develop the pharmaceutical sector in Kuwait and continue to provide the market with the latest medical products and services.”

CHU Nice is one of the leading hospitals in France. The hospital provides 1,900 beds, advance technical platforms, and supports a workforce of 7,500 healthcare workers and 1,000 medical doctors. CHU Nice is a member of the Nice Côte d'Azur University (UCA) and obtained its IDEX label (Initiatives of Excellence) from the National Research Agency in 2016.

AAW is one of the largest trading and commercial companies in Kuwait and operates in multiple FMCG, pharmaceutical, and retail sectors. The company’s pharmaceutical division is one of the oldest in the country with operations spanning over 50 years and a portfolio of world-renowned products from global pharmaceutical companies, such as Roche, Biotronik, Bioderma, Nuxe, and Takeda. The company is trusted by doctors, patients, and consumers across Kuwait and provides high-quality pharmaceutical products to combat infection, prevention, decreasing risks, and ensuring a healthier lifestyle.

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.